Lv41
680 积分 2023-09-29 加入
Zhenqi Fuzheng Granule targets the SCFAs-GPR109A axis to enhance PD-1 antibody efficacy via immunometabolic remodeling in colorectal cancer
20天前
已完结
Butyrate functions in concert with myeloid-derived suppressor cells recruited by CCR9 to alleviate DSS-induced murine colitis
21天前
已完结
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
5个月前
已完结
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
6个月前
已完结
Myeloid-derived suppressor cells in cancer and cancer therapy
7个月前
已完结
The lactate receptor HCAR1 drives the recruitment of immunosuppressive PMN-MDSCs in colorectal cancer
9个月前
已完结
Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer
1年前
已完结
Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA)
1年前
已完结
Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A phase II multi-center trial
1年前
已完结
A pooled analysis of datopotamab deruxtecan in patients with EGFR–mutated NSCLC
1年前
已完结